Pelargonic acid vanillylamide and rosuvastatin protect against oxidized low-density lipoprotein-induced endothelial dysfunction by inhibiting the NF-κB/NLRP3 pathway and improving cell-cell junctions.
Benzylamines
/ pharmacology
Caspase 1
/ metabolism
Cytoprotection
/ drug effects
Dose-Response Relationship, Drug
Enzyme Activation
/ drug effects
Fatty Acids
/ pharmacology
Human Umbilical Vein Endothelial Cells
/ cytology
Humans
Inflammasomes
/ metabolism
Intercellular Junctions
/ drug effects
Lipoproteins, LDL
/ pharmacology
NF-kappa B
/ metabolism
NLR Family, Pyrin Domain-Containing 3 Protein
/ metabolism
Oxidative Phosphorylation
/ drug effects
Reactive Oxygen Species
/ metabolism
Signal Transduction
/ drug effects
Endothelial dysfunction
Inflammasome
Nonivamide (pelargonic acid vanillylamide)
Oxidized low-density lipoprotein
Rosuvastatin
Journal
Chemico-biological interactions
ISSN: 1872-7786
Titre abrégé: Chem Biol Interact
Pays: Ireland
ID NLM: 0227276
Informations de publication
Date de publication:
25 Aug 2021
25 Aug 2021
Historique:
received:
27
02
2021
revised:
17
06
2021
accepted:
30
06
2021
pubmed:
5
7
2021
medline:
3
8
2021
entrez:
4
7
2021
Statut:
ppublish
Résumé
Oxidized low-density lipoprotein (ox-LDL) not only causes hyperlipidemia and contributes to atherosclerosis but also induces the endothelial dysfunction that leads to cardiovascular diseases. The nuclear factor-kappa B (NF-κB) pathway plays a key role in many chronic disorders and is a transcriptional factor in various inflammatory responses. The present study aimed to investigate the synergistic effects of pelargonic acid vanillylamide (PAVA) and rosuvastatin (RSV) on ox-LDL-induced inflammatory responses in human vascular endothelial cells (HUV-EC-C). HUV-EC-C were pretreated with PAVA or RSV and their combination for 2 h followed by ox-LDL for 24 h. The MTT assay was used to measure mitochondrial function. The DCFH-DA assay was used to evaluate oxidative phosphorylation, and western blotting was used to measured NF-κB/NLRP3 and related signaling pathways in HUV-EC-C. Ox-LDL induced lectin-type oxidized LDL receptor 1 (LOX-1) expression, NADPH oxidase 4 activation, and the overexpression of reactive oxygen species, which were inhibited by pretreatment with the combination of PAVA and RSV. Moreover, PAVA and RSV inhibited ox-LDL-induced NF-κBp65 activation. Ox-LDL induced NF-κB/NLRP3 pathway activation by inducing C-reactive protein expression, NLRP3 activation, caspase-1 activation, and IL-1β secretion, which were inhibited by pretreatment with the combination of PAVA and RSV. The combination of PAVA and RSV reduced ox-LDL-induced recruitment of monocytes to the site of inflammation, inhibited activation of the NLRP3 inflammasome, and ameliorated the impairment of cell-cell junctions through the NF-κB pathway. Our results suggest that the synergistic effects of PAVA and RSV provide a novel mechanism for the treatment of cardiovascular diseases.
Identifiants
pubmed: 34217687
pii: S0009-2797(21)00210-6
doi: 10.1016/j.cbi.2021.109572
pii:
doi:
Substances chimiques
Benzylamines
0
Fatty Acids
0
Inflammasomes
0
Lipoproteins, LDL
0
NF-kappa B
0
NLR Family, Pyrin Domain-Containing 3 Protein
0
Reactive Oxygen Species
0
oxidized low density lipoprotein
0
pelargonic acid vanillylamide
0
Caspase 1
EC 3.4.22.36
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
109572Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.